Disrupting vaccine logistics

James, Eric R.

doi:10.1093/inthealth/ihab010

Cited by 15 publications

(13 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sputnik V has other two key advantages that make its use potentially popular. Its low cost and the fact that Gamaleya makes its technology available for free, so countries can produce their own supplies [ 9 ] are critical aspects that can make this vaccine extremely popular in low- and middle-income countries.…”

Section: Prosmentioning

confidence: 99%

Controversy surrounding the Sputnik V vaccine

Cazzola

Rogliani

Mazzeo

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

The Sputnik V COVID-19 vaccine is a member of the so-called vector vaccines and uses two different vectors (Ad26 priming and Ad5 boost) to reduce the risk of a reduction in the effectiveness of the vaccination. Real life data indicate an efficacy of the vaccine above 97%. Low cost and no need for ultra-cold storage temperature temperatures are other pluses of the Sputnik V vaccine. However, there are also several important shortcomings that must be considered such as the possible reduction of its immunogenicity in the presence of very high Ad5 neutralizing antibody titres and the decrease with age of the antibody titres neutralizing the virus. Furthermore, there is emerging documentation that Sputnik V has a reduced neutralizing capacity against the Beta variant and all variants with the spike protein carrying the E484K substitution. Nevertheless, due to its characteristics, Sputnik V could be another useful means of satisfying the need for mass vaccination. However, it is imperative to document the efficacy and safety of the Sputnik V vaccine in individuals with high pre-existing anti-Ad26 and Ad5-neutralizing antibody titres and in those under the age of 18 or older than 60 years and be certain that Sputnik V does not cause the rare development of immune thrombotic thrombocytopenia. It is hoped that the now widespread use of this vaccine will generate a large pragmatic real-world study with data accessible to anyone interested in verifying them.

show abstract

Section: Prosmentioning

confidence: 99%

Controversy surrounding the Sputnik V vaccine

Cazzola

Rogliani

Mazzeo

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…Second, an important component of the vaccine deployment was the requirement for an ultracold chain (storage of vaccine at À70 °C), which poses extreme logistical challenges in resourceconstrained environments. Despite considerable efforts to avoid cold chain failures, it is plausible that fluctuations could have occurred and caused changes in vaccine effectiveness (21). Third, populations in this region may have a baseline level of filovirus seroreactivity that may enable a more robust response to Ebola vaccination (15,22).…”

Section: Significancementioning

confidence: 99%

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo

Hoff

Bratcher

Kelly

et al. 2022

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Significance This paper describes findings from a seroepidemiologic study involving a cohort of Ebola-vaccinated individuals from North Kivu, Democratic Republic of the Congo (DRC), who were studied as part of a collaborative effort between American and Congolese scientists and epidemiologists. Our study examines antibody response at 21 d and 6 mo postvaccination after single-dose rVSVΔG-ZEBOV-GP vaccination among Ebola virus disease–exposed and potentially exposed populations in the DRC. At 21 d of follow-up, 87.2% had an antibody response. Additionally, 95.6% demonstrated antibody persistence at 6 mo of follow-up. These findings give crucial evidence that antibody response and persistence after Ebola vaccination is robust in outbreak settings in the DRC, knowledge that significantly informs the use of vaccination for outbreak control.

show abstract

“…Second, the loss of doses is reduced. Eliminating inter-regional transport and regional intermediate storage hubs from the distribution network reduces the occurrence of storage temperature excursions . Considering that previous works report a 50% shipment-related waste of vaccine doses worldwide, reducing dose spoilage represents a very strong economic incentive.…”

Section: Cost Analysismentioning

confidence: 99%

“…In addition to the overall availability of vaccine doses, the lack of supply chain infrastructure in developing countries is a limitation to distributing vaccines to developing regions. ,, Deficiencies in supply chain infrastructure manifest themselves in a lack of air mail capacity, lack of local cold chain infrastructure, and unreliable power supply for cold storage. , In the past (outside the context of COVID-19), the World Health Organization (WHO) estimated that 50% of vaccine doses may be wasted worldwide due to problems related to storage and shipping . Clearly, solutions are required that enable both a reliable global supply and rapid deployment of vaccines while being flexible enough to respond to local outbreaks and new variants emerging in the future.…”

Section: Introductionmentioning

confidence: 99%

Mobile On Demand COVID-19 Vaccine Production Units for Developing Countries

Fahr

Peña-Benavides

Thiel

et al. 2022

Ind. Eng. Chem. Res.

View full text Add to dashboard Cite

Two years into the COVID-19 pandemic and more than one year after the approval of the first vaccine, bottlenecks in production and supply chain infrastructure continue to delay vaccination campaigns in the Global South. Mobile on Demand (MOD) vaccine manufacture may help quickly ramp up production capacity while bypassing infrastructure bottlenecks. Such decentralized small-scale factories can help tip the scales in the battle against COVID-19 and future pandemics. In this work, we designed two MOD vaccine manufacturing units based on a protein antigen expressed in yeast and in vitro transcription of mRNA. Each unit consists of three shipping containers and can produce on the order of 10,000 vaccine doses daily for competitive prices and in close proximity of their end users. Abandoning economies of scale may lead to a moderate increase in production costs that may be outweighed by reduced closed-vial dose wastage and an earlier protection of vulnerable populations.

show abstract

Disrupting vaccine logistics

Cited by 15 publications

References 4 publications

Controversy surrounding the Sputnik V vaccine

Controversy surrounding the Sputnik V vaccine

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo

Mobile On Demand COVID-19 Vaccine Production Units for Developing Countries

Contact Info

Product

Resources

About